Phaseline

Companies › Atlas Molecular Pharma

Atlas Molecular Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATL-001 (Ciclopirox oral solution)
Antifungal agent with anti-inflammatory and heme oxygenase-1 (HO-1) inducing properties
–Phase 1Congenital Erythropoietic Porphyria (CEP)May 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07024316ATL-001 (Ciclopirox oral solution)Phase 1Congenital Erythropoietic Porphyria (CEP)Metabolic and endocrineMay 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.